Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -959.76% is 53% above its 5-year average of -2056.57%, near the high end of its 5-year range (-18880.26%–0.00%).
13.66% below its 12-month average of -844.41%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -792.88%.
NET PROFIT MARGIN
-959.76%
NET PROFIT MARGIN AVG TTM
-844.41%
NET PROFIT MARGIN AVG 3Y
-1009.90%
NET PROFIT MARGIN AVG 5Y
-2056.57%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-13.66%
CURRENT VS 3Y AVG
+4.96%
CURRENT VS 5Y AVG
+53.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Lucid Diagnostics Inc.
Market Cap
$114.52M
Net Profit Margin
-959.76%
TTM Avg
-844.41%
3Y Avg
-1009.90%
5Y Avg
-2056.57%
Market Cap
$114.61M
Net Profit Margin
-114.77%
TTM Avg
-120.72%
3Y Avg
-96.63%
5Y Avg
-81.33%
Market Cap
$115.02M
Net Profit Margin
-422412.50%
TTM Avg
-387587.50%
3Y Avg
-197966.84%
5Y Avg
-131977.89%
Market Cap
$113.61M
Net Profit Margin
-175.78%
TTM Avg
-311.79%
3Y Avg
-369.50%
5Y Avg
-4193.27%
Market Cap
$113.30M
Net Profit Margin
-270.22%
TTM Avg
-342.92%
3Y Avg
-204.73%
5Y Avg
-136.49%
Market Cap
$116.32M
Net Profit Margin
-1030.42%
TTM Avg
-1409.68%
3Y Avg
-958.30%
5Y Avg
-801.33%
Market Cap
$116.57M
Net Profit Margin
-2955.63%
TTM Avg
-2231.78%
3Y Avg
-3480.44%
5Y Avg
-3216.57%
Market Cap
$111.14M
Net Profit Margin
-52.59%
TTM Avg
-29.17%
3Y Avg
-18.36%
5Y Avg
-9.63%
Market Cap
$118.05M
Net Profit Margin
-586.74%
TTM Avg
-215.13%
3Y Avg
-125.58%
5Y Avg
-83.72%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $114.52M | -959.76% | -844.41% | -1009.90% | -2056.57% |
| MaxCyte, Inc. (MXCT)vs › | $114.61M | -114.77% | -120.72% | -96.63% | -81.33% |
| Genelux Corporation (GNLX)vs › | $115.02M | -422412.50% | -387587.50% | -197966.84% | -131977.89% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.61M | -175.78% | -311.79% | -369.50% | -4193.27% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.30M | -270.22% | -342.92% | -204.73% | -136.49% |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.32M | -1030.42% | -1409.68% | -958.30% | -801.33% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | -2955.63% | -2231.78% | -3480.44% | -3216.57% |
| BGM Group Ltd. (BGM)vs › | $111.14M | -52.59% | -29.17% | -18.36% | -9.63% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.05M | -586.74% | -215.13% | -125.58% | -83.72% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $110.05M | -4416.22% | -2208.11% | -1104.06% | -736.04% |
Operating Margin
-1054.8%
Net Profit Margin
-959.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -792.88% |
| 2026-03-31 | -1107.40% |
| 2025-12-31 | -1081.52% |
| 2025-09-30 | -858.55% |
| 2025-06-30 | -381.69% |
| 2025-03-31 | -3249.76% |
| 2024-12-31 | -964.16% |
| 2024-09-30 | -1055.55% |
| 2024-06-30 | -1127.56% |
| 2024-03-31 | -1060.14% |
| 2023-12-31 | -1041.35% |
| 2023-09-30 | -1814.56% |
| 2023-06-30 | -7157.86% |
| 2023-03-31 | -3642.83% |
| 2022-12-31 | -13328.57% |
| 2022-09-30 | -18880.26% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | -6492.06% |
| 2021-12-31 | -3768.54% |
| 2021-09-30 | -3478.50% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2018-12-31 | 0.00% |
